Precigen Q4 net loss $25M, FY loss $96.8M; $163.7M cash; clinical progress

PRECIGEN, INC.

2021-FY EPS reported -$0.47 revenue$103,873,000

Q4 net loss from continuing ops $25.0M ($0.13/sh) vs $39.7M ($0.22/sh) year ago; full-year net loss $96.8M ($0.49/sh) vs $103.8M.
Cash, cash equivalents and investments totaled $163.7M as of Dec 31, 2021; net cash used in ops $55.8M in 2021, down from $77.0M in 2020.
January 2021 public offering of 17.25M shares raised gross proceeds of ~$129.4M; cash expected to fund operations well into 2023.
Clinical milestones: completed enrollment in PRGN-3006 AML, PRGN-3005 ovarian, and PRGN-2012 RRP studies; IND clearances for PRGN-3007 and PRGN-2012.
R&D expenses up 20% for the year; SG&A down 19%; non-core businesses (Trans Ova, Exemplar) increased revenues and profitability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.